Trials / Completed
CompletedNCT00735566
Antiangiogenic Factors in Gastric Cancer
The Role of Endogenous Antiangiogenic Factors in Gastric Cancer Progression
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 240 (actual)
- Sponsor
- National Cancer Center, Korea · Other Government
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
Endogenous antiangiogenic factors are related with gastric cancer progression.
Detailed description
Gastric cancers have been known to secrete the proangiogenic cytokine VEGF in vitro and in vivo. Tumor VEGF expression is correlated with the severity of disease in patients with gastric cancer and some authors have suggested using circulating VEGF as a prognostic factor or tumor marker.In addition to producing proangiogenic cytokines, recent data demonstrate that tumors can produce antiangiogenic cytokine as well. It has been suggested that, in humans, the generation of antiangiogenic compounds in the presence of a primary tumor suppresses the growth of distant metastases. This phenomenon has been demonstrated in mice and in patients with clear cell renal cancer, breast cancer, and colorectal cancer. However, the presence of endogenous antiangiogenic cytokines in patients with gastric cancer has not been reported.
Conditions
Timeline
- Start date
- 2006-04-01
- Primary completion
- 2008-07-01
- Completion
- 2012-01-01
- First posted
- 2008-08-15
- Last updated
- 2012-10-18
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00735566. Inclusion in this directory is not an endorsement.